WFM
CTIC

Wilmington Funds Management’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Wilmington Funds Management’s Portfolio CTIC Stock Details CTIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-1,140
Closed -$39K – 865
2014
Q1 		$39K Buy
+1,140
New +$39K ﹤0.01% 760

Other funds holding CTIC

EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
TA
Teachers Advisors New York $81.7B AUM 13.62% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wilmington Funds Management's CTIC Position: Q2 2014 in Review

Wilmington Funds Management sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q2 2014, closing a stake of 1,140 shares — an estimated $39K sold.

Wilmington Funds Management first reported a position in CTIC in Q1 2014 and held it in 1 quarter. The position peaked at $39K in Q1 2014. 89 funds tracked by Wall St. Rank hold CTIC as of Q2 2014.

  • Wilmington Funds Management reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q2 2014 after selling out during the quarter.
  • Wilmington Funds Management sold 1,140 CTI BioPharma Corp. (DE) Common Stock shares in Q2 2014, an estimated $39K.
  • Wilmington Funds Management first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q1 2014 and held it in 1 quarter.
  • Wilmington Funds Management's CTI BioPharma Corp. (DE) Common Stock position peaked at $39K in Q1 2014.
  • 89 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q2 2014.

Based on Wilmington Funds Management's 13F filing for Q2 2014, filed 13 Aug 2014.